Roche says Ocrevus (Ocrelizumab) failed Phase 3 study for relapsing MS and active secondary progressive disease in adults.
They don't know the effect it might have on children...adult recommendation only.
(1)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-